A5041516784- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Cardiovascular Syncope and Autonomic Disorders
- Psychosomatic Disorders and Their Treatments
- Olfactory and Sensory Function Studies
- Ophthalmology and Eye Disorders
- Long-Term Effects of COVID-19
- Neurological Complications and Syndromes
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience of respiration and sleep
- Neurological Disorders and Treatments
- COVID-19 and Mental Health
- Cerebral Venous Sinus Thrombosis
- Neurosurgical Procedures and Complications
- Retinal and Optic Conditions
- Sexual function and dysfunction studies
- Vestibular and auditory disorders
- Autoimmune Neurological Disorders and Treatments
- Nicotinic Acetylcholine Receptors Study
- Biochemical effects in animals
- Body Image and Dysmorphia Studies
- Health Systems, Economic Evaluations, Quality of Life
- Transcranial Magnetic Stimulation Studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
Universitat Autònoma de Barcelona
2016-2025
Vall d'Hebron Hospital Universitari
2016-2025
Vall d'Hebron Institut de Recerca
2016-2025
Universitat de Barcelona
2002-2025
Hebron University
2019-2024
Centre for Biomedical Network Research on Rare Diseases
2023
Oslo University Hospital
2023
Brigham and Women's Hospital
2023
Harvard University
2023
Hospital Valle del Nalón
2020-2021
Background Quality clinical trials form an essential part of the evidence base for treatment headache disorders. In 1991, International Headache Society Clinical Trials Standing Committee developed and published first edition Guidelines Controlled Drugs in Migraine. 2008, specific guidelines on chronic migraine. Subsequent advances drug, device, biologicals development, as well novel trial designs, have created a need revision migraine guidelines. Objective The present update is intended to...
Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief acute and preventive treatments. It is aim present document to provide a definition those migraines which are difficult-to-treat, create awareness existence this group patients, help Healthcare Authorities understanding implications, basis develop better pathophysiological support further therapeutic advances.Definitions were established consensus process using Delphi...
Objective To define headache characteristics and evolution in relation to COVID-19 its inflammatory response. Methods This is a prospective study, comparing clinical data biomarkers of patients with without headache, recruited at the Emergency Room. We compared baseline 6-week follow-up evaluate disease evolution. Results Of 130 patients, 74.6% (97/130) had headache. In all, 24.7% (24/97) severe pain migraine-like features. Patients more anosmia/ageusia (54.6% vs. 18.2%; p < 0.0001)....
The quality of clinical trials is an essential part the evidence base for treatment headache disorders. In 1991, International Headache Society Clinical Trials Standing Committee developed and published first edition Guidelines controlled drugs in migraine. Scientific developments medicine led to second third editions 2000 2012, respectively. current, fourth retains structure much content from previous editions. However, it also incorporates after as well feedback meetings with regulators,...
Clinical trials are a key component of the evidence base for treatment headache disorders. In 1991, International Headache Society Trials Standing Committee developed and published first edition Guidelines Controlled Drugs in Migraine. Advances drugs, devices, biologicals, as well novel trial designs, have prompted several updates over nearly 30 years since, including most recently controlled preventive chronic migraine (2018), acute attacks adults (2019), children adolescents (2019). The...
Background Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the duration headache in patients that presented during acute phase COVID-19. Methods This post-hoc multicenter ambisective study including from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months neurological follow-up. Results included 905 patients. Their median age was 51 (IQR 45–65), 66.5% were...
In an effort to improve migraine management around the world, International Headache Society (IHS) has here developed a list of practical recommendations for acute pharmacological treatment migraine. The are categorized into optimal and essential, in order provide options all possible settings, including those with limited access medications.
Background Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike many countries have reimbursement policies, which hinder to those who might respond. This study aimed investigate clinical factors associated with good excellent response anti-CGRP MAbs at 6 months. Methods European multicentre, prospective, real-world study, including high-frequency episodic or chronic (CM) patients treated since March 2018...
Raised levels of P/Q type voltage-gated calcium-channel (VGCC) antibodies were found in 16 (41%) 39 patients with paraneoplastic cerebellar degeneration (PCD) and Hu nine (23%). Seven the VGCC antibody-positive had Lambert-Eaton myasthenic syndrome (LEMS). 15 CSF samples antibodies, evidence intrathecal synthesis four. should be looked for PCD, even if there are no symptoms LEMS, may related to dysfunction.
OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with onabotulinumtoxinA poses challenges compared traditional therapy orally administered preventatives. The European Headache Federation identified an expert group that was asked to develop present guideline provide recommendations for use CM. recommend as effective and well-tolerated treatment Patients should preferably have tried two three other prophylactics before start...
Introduction Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with on basis of mechanistic rationale and pilot clinical data. Methods This multicentre study included a 4-week run-in period, 12-week double-blind period randomised treatment nVNS or sham, 24-week open-label nVNS. Patients were administer two 120-second stimulations bilaterally neck three times daily (6–8 hours apart). Results Of 477 enrolled patients, 332 comprised...
Introduction According to the IHCD-3β classification, chronic migraine (CM) is headache occurring on 15 or more days/month. Episodic (EM) can be divided into low frequency (LFEM) and high (HFEM) depending days suffered per month. Methods We performed a clinical comparison of characteristics according monthly suffered. Patients were three groups: LFEM (1-9 days/month), HFEM (10-14 days/month) CM (≥15 days/month). Results The analysis included 1109 patients. Previously reported differences...